Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
NCT00768859
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
111
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
HER2 Positive
Interventions
DRUG:
paclitaxel, trastuzumab and carboplatin
Sponsor
The Netherlands Cancer Institute